Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.
Saved in:
| Title: | Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy. |
|---|---|
| Authors: | Caldera F; Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Mogallapalli H; Department of Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Abusalim AR; Department of Medicine, Division of Hospital Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA., Farraye FA; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., Hayney MS; School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA. |
| Source: | Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2025 Nov 01; Vol. 16 (11), pp. e00924. Date of Electronic Publication: 2025 Nov 01. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101532142 Publication Model: Electronic Cited Medium: Internet ISSN: 2155-384X (Electronic) Linking ISSN: 2155384X NLM ISO Abbreviation: Clin Transl Gastroenterol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2155-384X |
|---|---|
| DOI: | 10.14309/ctg.0000000000000924 |
